|
|||||
|
Latest Insider Trading | Top Insider Trading Recent Week | Top 10% Owner Trading Recent Week | Filter |
Ticker | Owner | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
CTMX | Peterson Amy C. | EVP, Chief Development Officer | Mar 16 | Sale | 1.98 | 4,257 | 8,425 | 58,433 | Mar 20 06:43 PM |
CTMX | Peterson Amy C. | EVP, Chief Development Officer | Jul 20 | Sale | 1.42 | 7,463 | 10,612 | 62,690 | Jul 21 04:11 PM |
BGNE | Peterson Amy C. | CMO, Immuno-oncology | Dec 18 | Option Exercise | 29.10 | 10,141 | 295,103 | 10,141 | Dec 19 06:34 PM |
BGNE | Peterson Amy C. | CMO, Immuno-oncology | Dec 17 | Option Exercise | 29.10 | 9,859 | 286,897 | 9,859 | Dec 19 06:34 PM |
BGNE | Peterson Amy C. | CMO, Immuno-oncology | Dec 17 | Sale | 133.61 | 9,859 | 1,317,224 | 0 | Dec 19 06:34 PM |
BGNE | Peterson Amy C. | CMO, Immuno-oncology | Dec 18 | Sale | 133.75 | 10,141 | 1,356,312 | 0 | Dec 19 06:34 PM |
BGNE | Peterson Amy C. | CMO, Immuno-oncology | Nov 08 | Option Exercise | 29.10 | 14,711 | 428,090 | 14,711 | Nov 13 10:20 AM |
BGNE | Peterson Amy C. | CMO, Immuno-oncology | Nov 09 | Option Exercise | 29.10 | 13,222 | 384,760 | 13,222 | Nov 13 10:20 AM |
BGNE | Peterson Amy C. | CMO, Immuno-oncology | Nov 12 | Option Exercise | 29.10 | 12,067 | 351,150 | 12,067 | Nov 13 10:20 AM |
BGNE | Peterson Amy C. | CMO, Immuno-oncology | Nov 12 | Sale | 112.73 | 12,067 | 1,360,349 | 0 | Nov 13 10:20 AM |
BGNE | Peterson Amy C. | CMO, Immuno-oncology | Nov 09 | Sale | 120.49 | 13,222 | 1,593,163 | 0 | Nov 13 10:20 AM |
BGNE | Peterson Amy C. | CMO, Immuno-oncology | Nov 08 | Sale | 126.07 | 14,711 | 1,854,577 | 0 | Nov 13 10:20 AM |
BGNE | Peterson Amy C. | CMO, Immuno-oncology | Aug 23 | Sale | 169.12 | 5,769 | 975,666 | 0 | Aug 24 04:25 PM |
BGNE | Peterson Amy C. | CMO, Immuno-oncology | Nov 13 | Sale | 82.96 | 3,601 | 298,747 | 0 | Nov 15 08:11 PM |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite